A Phase 1 Trial of the Combination of the Heat Shock Protein-90 (HSP90) Inhibitor Onalespib (AT13387) and the Cyclin-Dependent Kinase (CDK) Inhibitor AT7519M in Patients With Advanced Solid Tumors

Study Description

This phase I trial studies the side effects and best dose of onalespib and CDKI AT7519 in treating patients with solid tumors that have spread from the primary site (place where they started) to other places in the body (metastatic) or cannot be removed by surgery. Onalespib and CDKI AT7519 may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.

Study Details

Registry ID:

NCT02503709

Conditions:

Advanced Malignant Solid Neoplasm, Metastatic Malignant Solid Neoplasm, Unresectable Solid Neoplasm

Phase:

Phase 1

Target Enrollment:

29 participants

Start Date:

September 30, 2016

Healthy Volunteers:

No

Study Locations (6 sites)

• Massachusetts General Hospital Cancer Center
  Boston, MassachusettsUnited States, United States
• Dana-Farber Cancer Institute
  Boston, MassachusettsUnited States, United States
• MedStar Georgetown University Hospital
  Washington, District of ColumbiaUnited States, United States
• National Cancer Institute Developmental Therapeutics Clinic
  Bethesda, MarylandUnited States, United States
• National Institutes of Health Clinical Center
  Bethesda, MarylandUnited States, United States
• Ohio State University Comprehensive Cancer Center
  Columbus, OhioUnited States, United States

Interested in Participating?

Check your eligibility and learn more about this study on TrialScreen.

View full study details and check eligibility →